FMS vs. DVA, SHC, AGL, PGNY, CO, VMD, OTRK, MGRX, BRTX, and MRAI
Should you be buying Fresenius Medical Care stock or one of its competitors? The main competitors of Fresenius Medical Care include DaVita (DVA), Sotera Health (SHC), agilon health (AGL), Progyny (PGNY), Global Cord Blood (CO), Viemed Healthcare (VMD), Ontrak (OTRK), Mangoceuticals (MGRX), BioRestorative Therapies (BRTX), and Marpai (MRAI). These companies are all part of the "miscellaneous health & allied services, not elsewhere classified" industry.
Fresenius Medical Care (NYSE:FMS) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.
DaVita has a net margin of 6.61% compared to Fresenius Medical Care's net margin of 2.48%. DaVita's return on equity of 68.52% beat Fresenius Medical Care's return on equity.
DaVita received 87 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 61.75% of users gave DaVita an outperform vote while only 54.05% of users gave Fresenius Medical Care an outperform vote.
Fresenius Medical Care currently has a consensus target price of $24.00, indicating a potential upside of 12.83%. DaVita has a consensus target price of $144.67, indicating a potential downside of 1.67%. Given Fresenius Medical Care's higher possible upside, analysts clearly believe Fresenius Medical Care is more favorable than DaVita.
In the previous week, Fresenius Medical Care had 6 more articles in the media than DaVita. MarketBeat recorded 14 mentions for Fresenius Medical Care and 8 mentions for DaVita. DaVita's average media sentiment score of 1.32 beat Fresenius Medical Care's score of 0.50 indicating that DaVita is being referred to more favorably in the news media.
DaVita has lower revenue, but higher earnings than Fresenius Medical Care. DaVita is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
8.3% of Fresenius Medical Care shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Fresenius Medical Care has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
Summary
DaVita beats Fresenius Medical Care on 13 of the 18 factors compared between the two stocks.
Get Fresenius Medical Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for FMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresenius Medical Care Competitors List
Related Companies and Tools
